A new PET tracer targeting carbonic anhydrase IX (CAIX) has demonstrated exceptional sensitivity and high tumor-to-background ...
Renal cell carcinoma is the most common form of kidney cancer. It can take time to fully process a diagnosis and what, exactly, it may mean. Developing a good understanding of your disease—and ...
A randomized phase 2 trial of nivolumab, relatlimab plus ipilimumab vs. nivolumab plus ipilimumab in first-line advanced renal cell carcinoma. This is an ASCO Meeting Abstract from the 2026 ASCO ...
Diagnosed With Advanced Renal Cell Carcinoma: Why You May Want a Second Opinion, and How to Find One
Many people with cancer can benefit from a second medical opinion. Those with advanced renal cell carcinoma (RCC), who are likely considering multiple treatment options, if not combinations of ...
A new analysis of U.S. military personnel included Black, White, and Hispanic adults newly diagnosed with primary stage I-III RCC between 1998 and 2014. Hispanic and White patients had similar rates ...
Arcus Biosciences has agreed to supply its investigational cancer-targeting drug to be evaluated in a Bristol Myers Squibb-sponsored trial in advanced kidney cancer. The drug, casdatifan, will be ...
For patients with primary localized renal cell carcinoma (RCC), especially those who aren’t good candidates for surgery, noninvasive or minimally invasive ablative treatments have emerged as important ...
In a recent study, mean sensitivity was 85.5% and specificity 87% for detection of clear-cell renal cell carcinoma. (HealthDay News) — ⁸⁹Zr-labeled monoclonal antibody ([⁸⁹Zr]Zr-girentuximab) for ...
Personalized cancer vaccine showed promising results, with all patients cancer-free at nearly three years follow-up. The vaccine targets unique cancer-specific antigens, effectively steering the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results